StreetAlpha.app
Home › Stocks › COYA

Coya Therapeutics, Inc. (COYA)

$2.95
▼ −1.01%
LAST CLOSE · NOV 20

Coya Therapeutics develops biologic treatments that aim to restore regulatory T cell function for patients with serious diseases. It last closed at $2.95 on Nov 20, down 1.01% on the day. The next earnings report for COYA is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, COYA reported EPS of -$0.45 on revenue of $234,134, with revenue down 93.4% from a year ago. Over its last 8 reports the stock moved an average of 3.2% the session after earnings.

AI Auto Pilots
Is COYA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold COYA.

Key Stats

Last 12 months
Results
Revenue
$4.7M
+17.6% vs a year ago
Net income
−$30.2M
−643.5% margin
EPS (diluted)
−$1.39
Operating margin
−675.3%
−$31.7M operating income
Valuation
Market cap
$69.2M
23.5M shares
P/E
–
No P/E while losing money
Price to sales
14.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$35.8M
At Sep 30
Shareholder equity
$33.6M
Shares outstanding
23.5M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $6.0M$6.0MFY2023FY2024: $3.6M$3.6MFY2024FY2025: $7.9M$7.9MFY2025

From COYA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
-$0.45
Quarter ended Sep 2026
Year ago EPS
-$0.13
Same quarter last year
Revenue
$234,134
−93.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.18Dec '24Mar 2025: -$0.44Mar '25Jun 2025: -$0.36Jun '25Sep 2025: -$0.13Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.32Mar '26Jun 2026: -$0.28Jun '26Sep 2026: -$0.45Sep '26Latest -$0.45
Revenue by quarter
Dec 2024: $1,952Dec '24Mar 2025: $257,884Mar '25Jun 2025: $163,616Jun '25Sep 2025: $3.6MSep '25Dec 2025: $4.0MDec '25Mar 2026: $251,147Mar '26Jun 2026: $243,745Jun '26Sep 2026: $234,134Sep '26Latest $234,134
How COYA moved after its last 8 reports
Average move the session after a report ±3.2%
Nov 10, 2026Time not announced−5.1%
Aug 11, 2026Time not announced+3.5%
May 12, 2026Time not announced+2.6%
Mar 16, 2026Time not announced−0.7%
Nov 12, 2025Time not announced+1.3%
Aug 12, 2025Time not announced−0.3%
May 13, 2025Time not announced−6.2%
Mar 18, 2025Time not announced−5.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on COYAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on COYA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on COYA

Technical Analysis

COYA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 12% below its 20 day and 40% below its 50 day average. It is 54% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the Pivot S1 at $2.86, and the nearest resistance the Pivot at $2.99.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 10.0%/day
Key levels
$6.6252 week high+124.4%
$4.53200 day average+53.6%
$4.42100 day average+49.8%
$4.1450 day average+40.3%
$3.47Swing high (Nov 10)+17.6%
$3.3020 day average+11.9%
$3.07Pivot R1+4.1%
$2.99Pivot+1.4%
$2.95Last close
$2.86Pivot S1−3.1%
$2.7252 week low−7.8%
$2.72Swing low (Nov 5)−7.8%
Indicators
RSI (14)32.89Weak, oversold below 30Neutral
MACD-0.33Above its signal lineBullish
Stochastic26.7Middle of its rangeNeutral
ADX (14)27.8Trending down
Williams %R-69.3Oversold below −80, overbought above −20Neutral
CCI (20)-71.7Oversold below −100, overbought above 100Neutral
Rate of change−1.3%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 10.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for COYA

What happened before

See how COYA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow COYA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How COYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for COYAHow many large options trades hit COYA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

COYA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼15 buying vs 23 selling
  • ▼Held by funds -1.6 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5254−3.7%
In funds' top 1000–
Held by funds31.5%33.1%−1.6 pts
New / increased6 / 95 / 14−21.1%
Reduced / sold out14 / 916 / 70.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COYA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

COYA Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 14, 2024David S SnyderCFOBuy1,800$7.19$13K
Nov 13, 2024Arun SwaminathanCEOBuy5,000$7.36$37K
Nov 11, 2024Arun SwaminathanCEOBuy5,000$7.34$37K
Nov 11, 2024Fred GrossmanChief Medical OfficerBuy2,710$7.37$20K
Every insider buy and sale for COYA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See COYA insider trades →

From SEC Form 4 filings by COYA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COYA is in one of them and how their past COYA trades turned out.

COYA in the AI portfolios
Loading…

COYA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COYA in an article yet. Here's the latest on the wider market.

COYA in the news

About Coya Therapeutics

Coya Therapeutics is a biotechnology company based in Houston, Texas. It is developing treatments that aim to restore the function of regulatory T cells, immune cells that help keep inflammation in check. Its lead candidate, COYA 302, is in clinical testing for amyotrophic lateral sclerosis and is also planned for frontotemporal dementia. The company's therapies are intended for patients with neurodegenerative, autoimmune and metabolic diseases.

Headquarters
Houston, TX